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ABSTRACT 
Objective. Evaluate hand osteoarthritis tools for core instrument set development. 
Methods. For OMERACT2018, a systematic literature review and advances in instrument validation 
were presented.  
Results. Visual analogue and numeric rating scales were considered valuable for pain and patient 
global assessment, despite heterogeneous phrasing and missing psychometric evidence for some 
aspects. Modified Intermittent and Constant Osteoarthritis Pain was lacking evidence. Michigan 
Hand Outcomes Questionnaire had advantages above other pain/function questionnaires. Hand 
Mobility in Scleroderma was valid, although responsiveness was questioned. Potential joint activity 
instruments were evaluated. 
Conclusion. The core instrument set development is progressing, and a research agenda was also 
developed.  
Page 3 of 28
For Peer Review
INTRODUCTION 
Hand osteoarthritis (OA) is a highly prevalent disorder, causing a considerable burden of disease(1). 
Simultaneous involvement of multiple hand joints and presence of different subsets (e.g., nodal, 
thumb base and erosive OA) make it difficult to study. To advance our understanding, high-quality 
studies with optimal outcome measurement are essential. 
The Outcome Measures in Rheumatology (OMERACT) Hand OA Working Group (WG), assembled in 
2010, endorsed a core domain set for clinical trials of symptom and structure modification and 
observational studies at OMERACT 2014(2), which was included in the Osteoarthritis Research 
Society International (OARSI) recommendations for design and conduct of clinical trials in hand 
OA(3). The core domain set includes six domains for all settings (pain, physical function, patient 
global assessment (PGA), health-related quality of life (HRQoL), joint activity, and hand strength), and 
two additional domains for trials of structure modification and observational studies (hand mobility 
and structural damage). HRQoL and hand mobility are not mandatory domains. 
A preliminary core instrument set was also proposed including visual analogue (VAS) or numeric 
rating scale (NRS) pain, Functional Index for Hand OA (FIHOA), tender joint count and pinch/grip 
strength(2). Subsequent goals of the WG were to (1) evaluate relevant instruments according to 
OMERACT Handbook (4), and (2) update the research agenda on final core instrument set 
selection(5). Progress was discussed at OMERACT 2018. 
 
METHODS 
Review of instruments measuring pain and patient global assessment (PGA) 
A systematic literature review (SLR) was performed (RW, BK, AA) including studies reporting on hand 
pain and PGA measured on VAS or NRS in patients with hand OA. A previous SLR on measurement 
properties of pain and function instruments in hand OA until January 2014 was used as a basis(6). 
Relevant manuscripts from that SLR were extracted. Additionally, medical literature databases 
(Pubmed, Embase, Web of Science, COCHRANE, CINAHL, Academic Search Premier, ScienceDirect) 
were searched from January 2014 to January 2018 applying similar methodology (see supplementary 
file). Psychometric features of the scales such as reliability, responsiveness, construct validity and 
clinical trial discrimination were extracted and evaluated according to OMERACT Handbook (4). 
These features were discussed at OMERACT 2018. Special attention was given to the phrasing and 
other details of the VAS/NRS question. 
Construct validity of the modified Intermittent and Constant OA Pain (ICOAP) (IKH,(7-9)) was studied 
in the Nor-Hand study to investigate whether constant and intermittent pain were separate 
constructs in hand OA. 
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Investigation of other potential core instruments 
Recent work was conducted by WG members on the relevant validity and psychometric properties of 
other tools: (1) Properties of the Michigan Hand Outcomes Questionnaire (MHQ) (FK,(10, 11)) were 
compared to more commonly used hand OA questionnaires, specifically Australian/Canadian Hand 
OA Index (AUSCAN) and FIHOA(12, 13); (2) Performance  of Hand Mobility in Scleroderma (HAMIS) 
and its responsiveness was compared to other mobility instruments (FK,(14)); (3) Assessment of 
tender joint count to measure joint activity (FK, (15, 16)). 
 
Research agenda 
Guided by discussions at OMERACT 2018, a research agenda was developed. 
 
RESULTS 
Domain pain and PGA: progress in instrument validation 
From the previous SLR, 32 relevant manuscript were selected providing data on VAS/NRS pain and/or 
PGA(6). Since January 2014, 18 relevant manuscripts were published and could be added (S1-S50, see 
reference list in supplements). Details of all included manuscripts can be found in supplementary 
table 1. Summary results of the search (supplementary figure 1) and psychometric features of both 
scales within these domains were discussed by the WG (table 1). VAS range 0-100 mm was the most 
studied scale (in 26/46 studies for pain and 10/15 studies for PGA). No study reported test-retest 
reliability data on the use of either scale in these domains. For pain, good construct validity of VAS 
was shown(S3, S24, S50), while only limited data were available for NRS(S41). Twenty-three(S1, S2, 
S4, S6-S13, S15-S18, S21, S22, S26, S37, S38, S42, S46) and eight studies(S15, S25, S28, S33, S34, S41, 
S45, S47) showed evidence for responsiveness of VAS and NRS, and 13(S7-S12, S17, S21, S22, S26, 
S37, S38, S46) and six studies(S14, S28, S33, S34, S41, S47) for clinical trial discrimination.  
For PGA, construct validity was not studied. Evidence to support responsiveness for VAS was 
available in ten(S3, S6, S12, S13, S15, S18, S22, S29, S38, S40), and three studies for NRS(S14, S28, 
S45) . The capacity to discriminate in clinical trials was shown for VAS PGA in agreement with the 
primary outcome in five studies(S12, S22, S29, S38, S40), while for NRS only one study supported 
this(S28).  
Strikingly, phrasing of the question accompanying VAS/NRS in both domains was very 
heterogeneous, and details were often not reported. For pain, substantial variety existed in which 
aspect(s) of pain were assessed (e.g., pain at rest or upon exertion, average or worst pain), location 
and joint(s) referred to (e.g.,target joints, dominant hand, both hands) and time of recall (undefined 
or ranging from current to 2 weeks) (supplementary table 2). Likewise, for PGA, time of recall was 
undefined in most studies (3/15 studies did specify (all 48 hours)) (supplementary table 3). After 
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presentation of these findings at OMERACT 2018, the WG proposed that clear standardized phrasing 
accompanying these instruments should be defined for pain and PGA. It was proposed that PGA 
should assess the impact of the disease on the patient’s general well-being. Review of results of 
previously held focus groups was suggested to explore what is most relevant to patients(17).  
Results of the validation study of the modified ICOAP were discussed at OMERACT 2018. Detailed 
results are presented elsewhere(9). In short, in hand OA patients, constant and intermittent pain 
largely overlapped and were not separate constructs, in contrast to the situation in knee and hip OA 
(7, 8). The existence of separate constructs in hand OA seemed clinically plausible, but might be 
influenced by hand OA location (finger versus thumb base) and involvement of multiple hand joints 
at different disease stages. It was suggested to seek more patient input, since the development of 
ICOAP was based on focus group discussions with patients with knee and hip OA, but not hand OA. 
However, previous focus groups of hand OA patients have already identified a range of pain 
concepts, such as fluctuating pain and psychological consequences of pain, which are not 
represented in the commonly used instruments to assess hand OA (17). 
Based on the available evidence, it was concluded that VAS and NRS are most likely the best 
instruments to measure pain and PGA. However, evidence about some essential psychometric 
properties is missing, in particular regarding reliability, construct validity for NRS pain/PGA, and 
clinical trial discrimination for NRS PGA.   
 
Evaluation of other potential core instruments and research agenda 
The results of comparison of MHQ with AUSCAN and FIHOA for measuring domains pain and function 
were discussed in light of OMERACT Filter 2.1(4) (table 2 and (11)). While displaying similar 
measurement properties, important advantages of MHQ above other instruments were that it can 
overcome issues of copyright (AUSCAN) and outdated questions (FIHOA). The possibility to propose 
more than one instrument for a core domain, with the accompanying risk of jeopardising 
standardisation, was discussed. 
Assessment of performance of HAMIS in comparison to other mobility instruments was published 
previously(14). Though HAMIS appeared the most useful to measure hand mobility compared to 
other instruments, the WG debated that responsiveness data are weak. Over a two-year period, 
limited change over time was observed(14), either indicating that the domain itself does not change, 
or that the instrument cannot detect this change. 
Progress in instrument development for joint activity is published in conference abstracts(15, 16). 
Lack of a well-accepted definition hampers instrument development for this domain. Potential 
instruments include inflammation on imaging (ultrasound, magnetic resonance imaging), pain upon 
palpation, self-reported painful joint count, soft tissue swelling, and pain while gripping. In the WG 
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discussion it was suggested that some instruments complement each other, and a combination may 
be useful. Prediction of radiological progression was proposed as an anchor to assess suitable 
instruments.  
 
Following discussion of these results, a research agenda was developed to guide future research 
(table 3). 
 
DISCUSSION 
Results of progress of development of a core instrument set for hand OA through investigation of the 
psychometric properties of candidate instruments according to OMERACT Handbook (4), assessing 
construct validity, reliability, responsiveness and clinical trial discrimination, were presented, 
discussed, and serve as the basis of an updated research agenda. 
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Domain Scale Construct validity Reliability Longitudinal construct validity (responsiveness) Clinical trial discrimination 
Studies showing 
significant correlation 
with:  
No of 
studies 
No of studies showing 
change 
No of studies 
showing no 
change, in 
disagreement 
with other 
outcomes 
Percentage of 
studies that 
detected 
change 
No of studies 
showing 
discrimination 
between arms 
in agreement 
with primary 
outcome 
No of studies 
not showing 
discrimination 
between arms 
in agreement 
with primary 
outcome 
No of studies 
showing 
discrimination 
between arms 
in 
disagreement 
with primary 
outcome 
No of studies 
not showing 
discrimination 
between arms 
in 
disagreement 
with primary 
outcome 
Pain VAS AUSCAN pain: r = 0.77 – 
0.81 (S3, S24, S50) 
0 23 (S1, S2, S4, S6-S13, 
S15-S18, S21, S22, 
S26, S37, S38, S42, 
S46)
#
 
3 (S31, S39, S44)  
 
88 13 (S7-S12, 
S17, S21, S22, 
S26, S37, S38, 
S46)  
6 (S1, S5, S6, 
S23, S32, S44)  
2 (S13, S42)  7 (S15, S19, 
S30, S39, S43, 
S48, S49)  
NRS AUSCAN pain: R² = 
0.606 (S41)  
AUSCAN function: R² = 
0.471 (S41)  
0 8 (S15, S25, S28, S33, 
S34, S41, S45, S47)  
0 100 6 (S14, S28, 
S33, S34, S41, 
S47)  
0 1 (S16)  1 (S25)  
PGA VAS 0 0 10 (S3, S6, S12, S13, 
S15, S18, S22, S29, 
S38, S40)
#
 
0 100 5 (S12, S22, 
S29, S38, S40)  
2 (S6, S40)  1 (S15)  0 
NRS 0 0 3 (S14, S28, S45)  0 100 1 [S28]  0 0 1 (S14)  
#
Saviola et al., 2017 (S38): no hard data shown, only described in full text; No: number; VAS: visual analogue scale; NRS: numeric rating scale; AUSCAN: Australian/Canadian Hand OA Index; r: 
coefficient of correlation; R²: correlation. S(number): refers to the reference in the supplementary reference list. 
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Table 2. Comparison of properties of Michigan Hand Outcomes Questionnaire (MHQ), Australian/Canadian Hand Osteoarthritis Index (AUSCAN), and 
Functional Index for Hand Osteoarthritis (FIHOA). 
 MHQ(10) AUSCAN(12) FIHOA(13) 
Domain: Pain 
Number of items 5 5 - 
Floor and ceiling effects* No (1.8% with lowest score, 0% with 
highest score)
No (1.8% with lowest score, 1.3% with 
highest score) 
- 
Aspect of pain assessed Frequency of experiencing pain in several 
situations (in general, during sleep or ADL) 
and whether it affects the respondent’s 
happiness. 
Pain severity during rest and several tasks 
(lifting, squeezing, turning, gripping) 
- 
Specific other comments No No - 
Domain: Function 
Number of items Overall hand function scale: 10 
ADL scale: 17 
9 10 
Floor and ceiling effects* No (subscales overall hand function/ADL: 
0%/0% with lowest score, 1.3%/3.1% with 
highest score) 
No (1.8% with lowest score, 0.3% with 
highest score) 
No (4.2% with lowest score, 0% with highest 
score) 
Aspect of function assessed Overall hand function scale: General 
questions of hand function, movement, 
strength and sensation. 
ADL scale: Ability to perform certain tasks 
(turning doorknob, picking up coin, 
holding glass of water, turning key in lock, 
holding heavy object with one hand, 
opening jar, buttoning shirt, using cutlery, 
carrying large and heavy objects, washing 
dishes, washing hair, tying shoelaces or 
knots); 4/12 grip strength tasks, 3/12 fine 
motor skills tasks. 
Ability to perform certain tasks (turning 
doorknobs, holding heavy object with one 
hand, buttoning shirt, using cutlery, 
carrying large and heavy obj cts, turning 
taps, fastening jewelry, wringing cloth); 
4/9 grip strength tasks, 2/9 fine motor 
skills tasks. 
Ability to perform certain tasks (turning key 
in lock, holding heavy objects, buttoning 
shirt, using cutlery, tying shoelaces or knots, 
cutting with scissors, clenching fist, sewing 
(women) / using screwdriver (men), writing 
for a long time, accepting a handshake); 
1/10 grip strength tasks, 4/10 fine motor 
skills tasks. 
Specific other comments Separate assessment of left and right 
hand. 
No Some items may be culturally challenging 
(accepting a handshake), or outdated 
(writing for more than 10 minutes; women 
sew and men use a screwdriver) 
General aspects 
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ADL, activities of daily living; N/A, not available; VAS, visual analogue scale. 
*Data reviewed in HOSTAS cohort (N=383), LUMC, Leiden, The Netherlands 
Recall period 1 week 48 hours Not specified 
Other available subscales 
(domain) 
Work performance (N/A) 
Aesthetics (Structural damage) 
Satisfaction (N/A) 
Stiffness (N/A) N/A 
Total number of items 58 15 10 
Method of scoring Includes normalizing to 0-100 scale, 
presented in user manual 
Dependent on version used (Likert scale, 
VAS), presented in user manual 
Simple addition of scores, user guide 
available online 
Costs Freely available for academic or non-profit 
institutions, permission needed before 
use (online application form) 
Copyrighted, payment of fee and 
permission needed before use 
No 
Available in multiple 
languages 
Yes Yes Yes 
Interpretability comments Pain scale has to be interpreted in 
opposite direction compared to other 
subscales 
No No 
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Table 3. Future research agenda to progress core instrument set selection for hand OA 
 
 
 Definition of standardized phrasing for VAS and NRS pain and PGA 
 Assessment of test-retest reliability of VAS and NRS pain and PGA 
 Investigation of construct validity for NRS pain and PGA, and discriminative capacity in 
clinical trials for NRS PGA 
 Investigation of validity of combinations of instruments to assess joint activity, including 
e.g., tender joints, self-reported painful joints, swollen joints, pain while gripping, and 
inflammatory signs on imaging 
 Assessment of reliability of soft tissue joint swelling in hand OA 
 Investigation of psychometric properties of grip and pinch strength to measure core 
domain hand strength 
 Review of available instruments to assess health-related quality of life in hand OA, and 
development of a disease-specific instrument 
 Investigation of the metric properties of ultrasound and magnetic resonance imaging 
 Investigation of the value of computer tomography 
VAS: visual analogue scale; NRS: numeric rating scale; PGA: patient global assessment; OA: 
osteoarthritis 
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Studies Source Population, 
No. Patients  
(% women), 
Mean Age, Yrs 
Definition of Hand OA and  
Inclusion criteria 
Study Design (Outcome) 
Duration 
Pain 
(VAS or NRS) 
(range) 
PGA 
(VAS or NRS) 
(range) 
      
Aitken, et al. 2018 (1) Secondary care,  
43 (77), 61 
ACR criteria RCT, cross over study (intervention = 
control)
§
, 
12 weeks 
VAS (0-100mm) - 
Baltzer, et al. 2016 (2) Secondary care,  
34 (94), 61 
Bony nodes, symptoms and 
radiographic 
Interventional study, 
8 weeks 
VAS (0-10cm) - 
Barthel, et al. 2010 (3) Secondary care,  
783 (80), 64 
ACR criteria, KL ≥ 1,  
symptoms ≥ 1 yr 
RCT (intervention > control)
*
,  
8 weeks 
VAS (0-100mm) VAS (0-100mm) 
Bjurehed, et al. 2017 (4) Primary care,  
49 (88), 69 
Radiographic and symtoms, 
physician’s diagnosis 
Interventional study,  
3 months 
VAS (0-100mm) - 
Brosseau, et al. 2005 (5) Secondary care,  
88 (78), 65 
ACR criteria, radiographic OA RCT (intervention = control),  
6 weeks 
VAS (0-100mm) - 
Chevalier, et al. 2015 
(6) 
Secondary care,  
85 (86), 63 
ACR criteria, KL ≥ 2, VAS pain ≥ 40, 
≥ 3 symptomatic joints > 3 months 
RCT (intervention = control),  
6 months 
VAS (0-100mm) VAS (0-100mm) 
Dilek, et al. 2013 (7) Secondary care,  
56 (89), 59 
ACR criteria RCT (intervention > control),  
3 weeks 
VAS (0-10cm) 
 
- 
Dreiser, et al. 1993 (8) Secondary care,  
60 (85), 59 
Radiographic OA RCT (intervention > control),  
2 weeks 
VAS (0-100mm) - 
Fioravanti, et al. 2014 
(9) 
Primary care,  
60 (87), 71 
ACR criteria, symptomatic RCT (intervention > control),  
2 weeks, FU 12 months 
VAS (0-100mm) - 
Gabay, et al. 2011 (10) Secondary care,  
162 (74), 63 
ACR criteria, radiographic OA ≥ 2 
joints ≥ 2 flares finger OA 
RCT (intervention > control),   
6 months 
VAS (0-100mm) - 
Garfinkel, et al. 1994 
(11) 
Not specified,  
25 (56), range 52-79 
ACR criteria RCT (intervention > control),  
10 weeks 
VAS - 
Grifka, et al. 2004 (12) Secondary care,  
594 (83), 62 
ACR criteria, symptomatic > 3 
months 
RCT (intervention > control),  
4 weeks 
VAS (0-100mm) VAS (0-100mm) 
Gyarmati, et al. 2017 
(13) 
Secondary care,  
47 (96), 64 
ACR criteria, OA pain hands > 3 
months 
RCT (intervention 1 = intervention 2), 
3 weeks 
VAS (0-100mm) VAS (0-100mm) 
Hennig, et al. 2015 (14) Secondary care,  
80 (100), 61 
ACR criteria, physician’s diagnosis RCT (intervention 1 > intervention 2), 
 3 months 
NRS (0-10) NRS (0-10) 
Horvath, et al. 2011 
(15) 
Secondary care,  
63 (81), 63 
ACR criteria, radiographic OA, pain 
≥ 3 months 
RCT (intervention > control), 3 weeks VAS (0-100mm) VAS (0-100mm) 
Kanat, et al. 2013 (16) Not specified,  
50 (100), 63 
ACR criteria RCT (intervention > control), 10 days NRS (1-10) - 
Kasapoglu, et al. 2017 Secondary care,  Radiographic OA, KL >2, VAS ≥ 4/10 RCT (intervention 1 > intervention 2), VAS (0-10cm) - 
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(17) 55 (93), 60 1 month 
Keen, et al. 2010 (18) Secondary care,  
36 (86), 58 
ACR criteria, radiographic OA Interventional study, 4 weeks VAS (0-10cm) VAS (0-10cm) 
Kjeken, et al. 2011 (19) Secondary care,  
70 (97), 61 
ACR criteria RCT (intervention = control),  
3 months 
VAS (0-100mm) - 
Kortekaas, et al. 2014 
(20) 
Secondary care,  
25 (76), 60 
ACR criteria Observational, FU 3 months VAS (0-100mm) - 
Kovács, et al. 2012 (21) Secondary care,  
45 (93), 59 
ACR criteria, KL ≥ 2 in ≥ 2 joints, 
VAS pain ≥ 30 
RCT (intervention > control), 3 weeks VAS (0-100mm) - 
Kvien, et al. 2008 (22) Secondary care,  
83 (93), 60 
ACR criteria, KL ≥ 2, ≥ 1 
swollen/tender joint, VAS pain ≥ 30 
RCT (intervention > control), 42 days VAS (0-100mm) VAS (0-100mm) 
Lee, et al. 2017 (23) Secondary care,  
196 (86), 58 
ACR criteria, KL ≥ 2 RCT (intervention = control),  
24 weeks 
VAS (0-100mm) - 
Moe, et al. 2010 (24) Secondary care,  
128 (91), 69 
ACR criteria Observational, cross sectional VAS (0-100mm) - 
Moe et al. 2016 (25) Secondary care,  
391 (86), 61 
ACR criteria RCT (intervention > control), 1 yr NRS (0-10) - 
Myrer, et al. 2011 (26) Volunteers,  
35 (77), 64 
ACR criteria, FIHOA > 5 RCT (intervention > control), 4 weeks VAS (0-100mm) - 
Neuprez, et al. 2015 
(27) 
Tertiary care,  
203 (90), 69 
ACR criteria Observational, cross-sectional VAS (0-100mm) - 
Osteras, et al. 2014 (28) Population based,  
130 (90), 66 
ACR criteria RCT (intervention > control),  
12 weeks 
NRS (0-10) NRS (0-10) 
Park, et al. 2016 (29) Secondary care,  
130 (90), 66 
ACR criteria RCT (intervention > control),  
12 weeks 
- VAS (0-100mm) 
Pastinen, et al. 1988 
(30) 
Secondary care,  
29 (79), 58 
Clinical/ radiographic finger OA RCT (intervention > control),  
14 weeks 
VAS (0-10cm) - 
Poiraudeau, et al. 2001 
(31) 
Secondary care,  
89 (91), 63 
ACR criteria Observational, FU 6 months VAS (0-100mm) - 
Romero-Cerecero, et al. 
2013 (32) 
Not specified,  
113 (95), 62 
ACR criteria, radiographic OA ≥ 2 IP 
joints, VAS ≥40, FIHOA ≥ 5  
RCT (intervention = control),  
6 weeks 
VAS (0-10cm) - 
Rothacker, et al. 1994 
(33) 
Not specified,  
49 (84), 66 
Physician diagnosed/radiographic 
OA, symptoms 
RCT (intervention > control),  
FU 15-120 min (after cream) 
NRS (1-5) - 
Rothacker, et al. 1998 
(34) 
Secondary care,  
81 (74), 61 
Physician diagnosed OA, symptoms RCT (intervention > control),  
FU 30-120 min (after cream) 
NRS (1-5) - 
Sautner, et al. 2004 (35) Secondary care,  
60 (73), 62 
ACR criteria Observational, cross-sectional - VAS (0-100mm) 
 
Sautner, et al. 2009 (36) Secondary care,  
66 (77), 58 
ACR criteria Observational, cross-sectional - VAS (0-100mm) 
 
Saviola, et al. 2012 (37) Secondary care,  Radiographic erosive OA ≥ 2 joints, RCT (intervention 1 > intervention 2), VAS (0-10cm) - 
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- : not included; 
*
Intervention group performed better than control group, according to the primary outcome measure. 
§
Intervention group did not perform better than control group, 
according to the primary outcome measure. OA: osteoarthritis; Yr(s): year(s); VAS: visual analogue score; NRS: numeric rating scale; PtGA: patient global assessment; ACR: American College of 
Rheumatology; RCT: randomized controlled trial; KL: Kellgren and Lawrence; IP: interphalangeal; FU: follow up; CT: clinical trial; FIHOA: Functional Index for Hand OA 
 
38 (95), 61 VAS ≥40 1 and 2 yr 
Saviola, et al. 2017 (38) Secondary care,  
40 (93), 70 
Radiographic erosive OA > 1 IP 
joints, VAS ≥ 4/10 
RCT (intervention 1 > intervention 2), 
6 months 
VAS (0-10cm) VAS (0-10cm) 
Schnitzer, et al. 1994 
(39) 
Not specified,  
59 (68), 68 
Radiographic/ 
physical OA findings 
RCT (intervention > control),  
9 weeks 
VAS (0-100mm) - 
Shin, et al. 2013 (40) Secondary care,  
86 (97), 58 
ACR criteria RCT (intervention = control),  
12 weeks 
- VAS (0-100mm) 
Sofat, et al. 2017 (41) Secondary care,  
65 (80), 63 
ACR criteria RCT (intervention 1 >  intervention 2 
> control), 12 weeks 
NRS (0-10) - 
Spolidoro Pashoal, et al. 
2015 (42) 
Secondary care,  
60 (97), 61 
ACR criteria RCT (intervention 1 > intevention 2), 
12 weeks 
VAS (0-10cm) - 
Stamm, et al. 2002 (43) Secondary care,  
40 (88), 60 
ACR criteria RCT (intervention > control),  
3 months 
VAS (0-100mm) - 
Stange-Rezende, et al. 
2006 (44) 
Secondary care,  
45 (93), 60 
ACR criteria RCT (intervention = control),  
3 weeks 
VAS (0-100mm) - 
Tubach, et al. 2012 (45) Secondary care,  
249 (88), 64 
ACR criteria Interventional, FU 4 weeks NRS (0-10) NRS (0-10) 
Van Velden, et al. 2015 
(46) 
Primary care,  
100 (not specified), 65 
ACR criteria RCT, cross over study (intervention > 
control), 56 days 
VAS (0-10cm) - 
Watt, et al. 2014 (47) Secondary care,  
26 (88), 63 
ACR criteria, NRS pain ≥ 2, 
radiograhic deformity 
CT (intervention > control),  
3 months 
NRS (0-10) - 
Wenham, et al. 2012 
(48) 
Not specified,  
70 (81), 61 
ACR criteria RCT (intervention = control), 4 weeks VAS (0-100mm) - 
Widrig, et al. 2007 (49) Primary and secundary 
care, 204 (74), 64 
ACR criteria, radiographic OA ≥ 2 
joints, VAS ≥ 40, FIHOA ≥ 5 
RCT (intervention = control), 3 weeks VAS (0-100mm) - 
Wittoek, et al. 2009 
(50) 
Secundary care,  
72 (89), 62 
ACR criteria Observational, cross-sectional VAS (0-100mm) - 
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Supplementary Table 2: Details of phrasing of question accompanying VAS or NRS pain  
 Reference Scale Explicite 
phrasing
§
 
Time of 
recall 
Other details 
RCT/Interventional studies 
Aitken, et al. 2018 (1) VAS (0-100mm) Yes 1 week  
Baltzer, et al. 2016 (2) VAS (0-10) No ND  
Barthel, et al. 2010 (3) VAS (0-100mm) No 24 hours Dominant hand 
Bjurehed, et al. 2017 (4) VAS (0-100mm) No current At rest 
Brosseau, et al. 2005 (5) VAS (0-100mm) No ND Pain intensity 
Chevalier, et al. 2015 (6) VAS (0-100mm) Yes 24 hours Global pain 
Dilek, et al. 2013 (7) VAS (0-10 cm) No 48 hours Pain at rest and during 
daily activity, both hands 
and hands separately 
Dreiser, et al. 1993 (8) VAS (0-100mm) No ND Overall spontaneous pain 
Fioravanti, et al. 2014 (9) VAS (0-100mm) No ND  
Gabay, et al. 2011 (10) VAS (0-100mm) No ND Global spontaneous hand 
pain 
Garfinkel, et al. 1994 (11) VAS  No ND Hand pain at rest and 
during activity 
Grifka, et al. 2004 (12) VAS (0-100mm) Yes 24 hours Pain intensity 
In target hand 
Gyarmati, et al. 2017 (13) VAS (0-100mm) No ND At rest and on exertion 
Hennig, et al. 2015 (14) NRS (0-10) No ND  
Horváth, et al. 2011 (15) VAS (0-100mm) No ND Severity of pain at rest 
and upon exertion; in 
small hand joints of the 
hands 
Kanat, et al. 2013 (16) NRS (1-10) No ND Hand pain at rest and on 
use 
Kasapoglu, et al. 2017 (17) VAS (0-10cm) No ND  
Keen, et al. 2010 (18) VAS (0-10cm) No ND Most painful joint, all 
joints of both hands 
Kjeken, et al. 2011 (19) VAS (0-100mm) No ND  
Kovács, et al. 2012 (21) VAS (0-100mm) No ND  
Kvien, et al. 2008 (22) VAS (0-100mm) Yes 48 hours Pain intensity 
Lee, et al. 2017 (23) VAS (0-100mm) No 24 hours  
Moe, et al. 2016 (25) NRS (0-10) No ND  
Myrer, et al. 2011 (26) VAS (0-100mm) Yes 1 week, 
current 
Pain at rest, pain upon 
movement, current pain 
Osteras, et al. 2014 (28) NRS (0-10) No ND  
Pastinen, et al. 1988 (30) VAS (0-10cm) No ND Pain provoked by grip and 
pinch strength tests 
Romero-Cerecero, et al. 
2013 (32) 
VAS (0-10cm) No ND Pain intensity 
Rothacker, et al. 1994 (33) NRS (1-5) No Immediately  
Rothacker, et al. 1998 (34) NRS (1-5) No ND  
Saviola, et al. 2012 (37) VAS (0-10cm) No ND  
Saviola, et al. 2017 (38) VAS (0-10cm) No ND  
Schnitzer, et al. 1994 (39) VAS (0-100mm) No ND Level of pain 
Sofat, et al. 2017 (41) NRS (0-10) No ND  
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Spolidoro Pashoal, et l. 
2015 (42) 
VAS (0-10cm) No ND Pain at rest, on 
movement 
Stamm, t l. 2002 (43) VAS (0-100mm) No ND  
Stange-Rezende, t l. 
2006 (44) 
VAS (0-100mm) No ND General level of pain 
Tubach, t l. 2012 (45) NRS (0-10) Yes 48hours  
Van Velden, t l. 2015 
(46) 
VAS (0-10) No ND  
Watt, t l. 2014 (47) NRS (0-10) No 1 week Average pain, worst pain 
Wenham, t l. 2012 (48) VAS (0-100mm) Yes 48 hours, 
2 weeks 
Average pain both hands, 
in the most painful joints, 
at 1st CMC 
Widrig, t l. 2007 (49) VAS (0-100mm) Yes 24 hours Finger level 
Obsrvtionl studis 
Kortekaas, t l. 2014 (20) VAS (0-100mm) No ND  
Moe, t l. 2010 (24) VAS (0-100mm) No ND  
Neuprez, t l. 2015 (27) VAS (0-100mm) No ND Global assessment of pain 
Poiraudeau, t l. 2001 
(31) 
VAS (0-100mm) No ND Pain intensity 
Wittoek, t l. 2009 (50) VAS (0-100mm) No 1 week Global pain, both hands 
VAS: visual analogue scale; NRS: numeric rating scale; ND: not defined 
 
§
 Explicit phrasing of scales in domain pain: 
- On this lin , wh r  would you rt  your pin, using th  lst 7 dys s  tim frm ? (1) 
- Wht is th  globl l v l of pin in your hnds in th  pst 24 hours? (6) 
- Indicate the most pain from your OA in the target hand over the previous 24hours? (12) 
- How would you describe the intensity of your joint pain during the last 2 days? (22) 
- How would you estimate your perception of average ‘pain at rest’ and average ‘pain with 
movement’ over the week prior to the assessment? (26) 
- Circle the number that best describes the pain you felt due to your hand osteoarthritis 
during the last 48 hours? (45) 
- Indicate the level of pain in the hands during the last 48 hours/ last 2 weeks? (48)  
- Indicate the level of pain in the most painful joint during the last 48 hours? (48) 
- Indicate the level of pain at the 1st CMC joint during the last 48 hours? (48) 
- Indicate the most intense pain in the previous 24 hours in the worst affected finger? (49) 
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Supplementary Table 3: Details of phrasing of question accompanying VAS or NRS PGA 
Reference Scale Exact 
phrasing
§
 
Time of 
recall 
Other comments 
RCT/Interventional studies 
Barthel, et al. 2010 (3) VAS (0-100mm) Yes ND Global assessment of 
disease activity 
Chevalier, et al. 2015 (6) VAS (0-100mm) No ND  
Griftka, et al. 2004 (12) VAS (0-100mm) No ND Global assessment of 
disease activity 
Gyermati, et al. 2017 (13) VAS (0-100mm) No ND  
Hennig, et al. 2015 (14) NRS (0-10) No ND Global assessment of 
disease activity 
Horváth, et al. 2011 (15) VAS (0-100mm) No ND  
Keen, et al. 2010 (18) VAS (0-10 cm) No ND  
Kvien, et al. 2008 (22) VAS (0-100mm) Yes 48 hours  
Osteras, et al. 2014 (28) NRS (0-10) No ND Global assessment of 
disease activity and disease 
activity affecting activities 
in daily life 
Park, et al. 2016 (29) VAS (0-100mm) No ND General health 
Saviola, et al. 2017 (38) VAS (0-10 cm) No ND Global assessment of 
disease activity 
Shin, et al. 2013 (40) VAS (0-100mm) No ND  
Observational studies 
Sautner, et al. 2004 (35) VAS (0-100mm) No ND  
Sautner, et al. 2009 (36) VAS (0-100mm) Yes 48 hours  
Tubach, et al. 2012 (45) NRS (0-10) Yes 48 hours  
VAS: visual analogue scale; NRS: numeric rating scale; ND: not defined 
§
 Explicit phrasing of scales in domain PGA: 
- Considering all the ways ostorthritis of your hands ffects you, please indicat with an ‘X’ 
through the horizontl lin how well are you doing? (3) 
- We ask you to vlut the activity of your ostorthritis ovr the last 2 dys? When you 
tk ll symptoms into considrtion, how will you evaluat your condition? (22) 
- Pls indicat how severe you are compromised by your hand ostorthritis during the last 
48 hours? (36) 
- Considering all the ways your hand ostorthritis has affectd you during the last 48 hours, 
circle the numbr that bst dscribes how you have been doing? (45) 
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STATEMENT OF CONTRIBUTION 
We declare that this manuscript presents substantial new information that is evaluable by peer 
review. 
Main findings: This report includes the results of a recent systematic literature review on 
instruments (visual analogue and numeric rating scale) in the domains pain and patient global 
assesments in hand osteoarthritis (OA). Also in other domains, progress in validation of certain 
instruments has been made. Michigan Hand Outcomes Questionnaire had advantages above other 
pain/function questionnaires. Hand Mobility in Scleroderma was valid, although responsiveness was 
questioned. 
What is novel: This report gives an overview of new evidence contributing to instrument validation in 
certain domains in hand OA. The discussion and proposed research agenda of OMERACT 2018 is 
reported. 
How it advances published research to date: A good overview is provided of where remaining gaps 
exist for further validation of several instruments before final core instrument set selection in hand 
OA. The discussions held at OMERACT 2018 serve as a basis for the future research agenda. 
Status regarding prior publication/submission elsewhere: This work was not previously published or 
submitted elsewhere. 
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